207 related articles for article (PubMed ID: 31319483)
21. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity.
Gee RH; Spinks JN; Malia JM; Johnston JD; Plant NJ; Plant KE
Toxicology; 2015 Mar; 329():40-8. PubMed ID: 25578243
[TBL] [Abstract][Full Text] [Related]
23. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
24. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways.
Kotamraju S; Williams CL; Kalyanaraman B
Cancer Res; 2007 Aug; 67(15):7386-94. PubMed ID: 17671209
[TBL] [Abstract][Full Text] [Related]
25. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin.
Hu WL; Qiao SB; Li JJ
Cytokine; 2007 Dec; 40(3):201-6. PubMed ID: 18023360
[TBL] [Abstract][Full Text] [Related]
26. Effects of mevalonate kinase interference on cell differentiation, apoptosis, prenylation and geranylgeranylation of human keratinocytes are attenuated by farnesyl pyrophosphate or geranylgeranyl pyrophosphate.
Li M; Min W; Wang J; Wang L; Li Y; Zhou N; Yang Z; Qian Q
Exp Ther Med; 2020 Apr; 19(4):2861-2870. PubMed ID: 32256770
[TBL] [Abstract][Full Text] [Related]
27. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases.
Ghittoni R; Patrussi L; Pirozzi K; Pellegrini M; Lazzerini PE; Capecchi PL; Pasini FL; Baldari CT
FASEB J; 2005 Apr; 19(6):605-7. PubMed ID: 15677697
[TBL] [Abstract][Full Text] [Related]
28. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.
Macaulay RJ; Wang W; Dimitroulakos J; Becker LE; Yeger H
J Neurooncol; 1999 Mar; 42(1):1-11. PubMed ID: 10360474
[TBL] [Abstract][Full Text] [Related]
29. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation.
Maeda T; Kawane T; Horiuchi N
Endocrinology; 2003 Feb; 144(2):681-92. PubMed ID: 12538631
[TBL] [Abstract][Full Text] [Related]
30. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
Eberlein M; Heusinger-Ribeiro J; Goppelt-Struebe M
Br J Pharmacol; 2001 Aug; 133(7):1172-80. PubMed ID: 11487529
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA.
Porter KE; Turner NA; O'Regan DJ; Balmforth AJ; Ball SG
Cardiovasc Res; 2004 Mar; 61(4):745-55. PubMed ID: 14985071
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension.
Liu WH; Xu XH; Luo Q; Zhang HL; Wang Y; Xi QY; Zhao ZH; Liu ZH
Clin Exp Hypertens; 2018; 40(3):224-230. PubMed ID: 29319354
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A.
Wang W; Macaulay RJ
Int J Cancer; 1999 Jul; 82(3):430-4. PubMed ID: 10399961
[TBL] [Abstract][Full Text] [Related]
34. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.
Greenaway JB; Virtanen C; Osz K; Revay T; Hardy D; Shepherd T; DiMattia G; Petrik J
Oncotarget; 2016 Jul; 7(30):47343-47365. PubMed ID: 27329838
[TBL] [Abstract][Full Text] [Related]
35. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
36. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products.
Liang YJ; Shyu KG; Wang BW; Lai LP
Cardiology; 2008; 110(3):182-90. PubMed ID: 18057884
[TBL] [Abstract][Full Text] [Related]
37. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages.
Veillard NR; Braunersreuther V; Arnaud C; Burger F; Pelli G; Steffens S; Mach F
Atherosclerosis; 2006 Sep; 188(1):51-8. PubMed ID: 16321392
[TBL] [Abstract][Full Text] [Related]
38. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
[TBL] [Abstract][Full Text] [Related]
39. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J
Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096
[TBL] [Abstract][Full Text] [Related]
40. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice.
Cho SJ; Kim JS; Kim JM; Lee JY; Jung HC; Song IS
Int J Cancer; 2008 Aug; 123(4):951-7. PubMed ID: 18521906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
